Literature DB >> 20930749

Peering into the aftermath: JAKi rips STAT3 in cancer.

Florian R Greten1, Michael Karin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20930749     DOI： 10.1038/nm1010-1085

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.

Authors:  A Pardanani
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

Review 3.  NF-kappaB: linking inflammation and immunity to cancer development and progression.

Authors:  Michael Karin; Florian R Greten
Journal:  Nat Rev Immunol       Date:  2005-10       Impact factor: 53.106

Review 4.  Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Authors:  Hua Yu; Marcin Kortylewski; Drew Pardoll
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

5.  Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades.

Authors:  M Digicaylioglu; S A Lipton
Journal:  Nature       Date:  2001-08-09       Impact factor: 49.962

6.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

7.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

Authors:  Julia Bollrath; Toby J Phesse; Vivian A von Burstin; Tracy Putoczki; Moritz Bennecke; Trudie Bateman; Tim Nebelsiek; Therese Lundgren-May; Ozge Canli; Sarah Schwitalla; Vance Matthews; Roland M Schmid; Thomas Kirchner; Melek C Arkan; Matthias Ernst; Florian R Greten
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

8.  Autocrine IL-6 signaling: a key event in tumorigenesis?

Authors:  Sergei Grivennikov; Michael Karin
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

Review 9.  IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis.

Authors:  Julia Bollrath; Florian R Greten
Journal:  EMBO Rep       Date:  2009-11-06       Impact factor: 8.807

Review 10.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716
View more
  7 in total

1.  CXCR4-mediated Stat3 activation is essential for CXCL12-induced cell invasion in bladder cancer.

Authors:  Hai-bo Shen; Zheng-qin Gu; Kang Jian; Juan Qi
Journal:  Tumour Biol       Date:  2013-03-23

2.  Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.

Authors:  Uksha Saini; Shan Naidu; Adam C ElNaggar; Hemant Kumar Bid; John J Wallbillich; Kristin Bixel; Chelsea Bolyard; Adrian A Suarez; Balveen Kaur; Periannan Kuppusamy; John Hays; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran
Journal:  Oncogene       Date:  2016-06-13       Impact factor: 9.867

Review 3.  Targeting the tumor microenvironment: JAK-STAT3 signaling.

Authors:  Eirini Bournazou; Jacqueline Bromberg
Journal:  JAKSTAT       Date:  2013-04-01

4.  AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells.

Authors:  Sarah K Maenhout; Stephanie Du Four; Jurgen Corthals; Bart Neyns; Kris Thielemans; Joeri L Aerts
Journal:  Oncotarget       Date:  2014-08-30

5.  Overexpression of a Long Non-Coding RNA BC037916 is Associated with Pancreatic Tumorigenesis and Poor Prognosis.

Authors:  Gang Chen; Litao Xu; Guanxiong Ye; Junhua Lin; Zhiqiang Meng; Yehua Shen
Journal:  Onco Targets Ther       Date:  2021-01-05       Impact factor: 4.147

Review 6.  Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

Authors:  Paul Beinhoff; Lavannya Sabharwal; Vindhya Udhane; Cristina Maranto; Peter S LaViolette; Kenneth M Jacobsohn; Susan Tsai; Kenneth A Iczkowski; Liang Wang; William A Hall; Scott M Dehm; Deepak Kilari; Marja T Nevalainen
Journal:  Cancers (Basel)       Date:  2021-10-17       Impact factor: 6.575

7.  Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system.

Authors:  Li-Yu D Liu; Li-Yun Chang; Wen-Hung Kuo; Hsiao-Lin Hwa; Yi-Shing Lin; Meei-Huey Jeng; Don A Roth; King-Jen Chang; Fon-Jou Hsieh
Journal:  Cancer Inform       Date:  2014-01-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.